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Relapse after allogeneic hematopoietic stem cell transplantation (HSCT) is a major concern in myelodysplastic
syndromes (MDS), but the role of Wilms tumor gene 1 (WT1) as a predictive marker for post-HSCT relapse
remains to be validated. We measured WT1 transcript levels by real-time quantitative PCR from marrow
samples of 82 MDS patients who underwent transplantation between 2009 and 2013. Pre-HSCT WT1
expression weakly correlated with marrow blast counts or International Prognostic Scoring System scores and
failed to predict post-transplantation relapse. Regarding post-HSCT WT1, transcript levels of relapsed patients
were signiﬁcantly higher in comparison to those in remission. Further analysis using receiver operating
characteristics curves showed that higher (>154 copies/104ABL) 1-month post-HSCT WT1 resulted in a higher
3-year relapse rate (47.2% versus 6.9%, P < .001) with poorer disease-free survival (DFS) and overall survival at
3 years (41.7% versus 79.0% and 54.3% versus 82.1%, P ¼ .003 and P ¼ .033, respectively). Multivariate analysis
after adjusting for pre-HSCT karyotype and chronic graft-versus-host disease (GVHD) also revealed that
higher 1-month post-HSCT WT1 was an independent predictive marker for subsequent relapse (P ¼ .002) and
poorer DFS (P ¼ .010). In the higher 1-month post-HSCT WT1 subgroup, patients with chronic GVHD showed
lower relapse rate and favorable survival outcome. One month post-HSCT WT1 expression was a useful
marker for minimal residual disease and relapse prediction in association with chronic GVHD in the context of
HSCT for MDS.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Several therapeutic options, including growth factors,
lenalidomide, azanucleosides, intensive chemotherapy, and
immunosuppressive therapy, have been used to treat mye-
lodysplastic syndromes (MDS). However, allogeneic he-
matopoietic stem cell transplantation (allo-HSCT) is still
known to be the only curative treatment and the results
show prolonged disease-free survival (DFS) rates of approx-
imately 30% to 50% [1-3]. The recent introduction of high-
resolution sequenced-based typing of human leukocyteedgments on page 466.
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ty for Blood and Marrow Transplantation.antigen, as well as reduced-intensity conditioning (RIC)
regimens and improvement of supportive modalities, have
reduced treatment-relatedmortality [4]. Therefore, relapse is
now considered to be a major cause of treatment failure after
allo-HSCT. Previous studies reported a relapse rate of 5% to
20% in early MDS and up to 60% in advanced MDS, and they
suggested MDS stage, bone marrow (BM) blast counts,
advanced age, and cytogenetics are risk factors for relapse
[1,5-7]. For patients at high risk, various transplantation
strategies can be applied, including modiﬁcation of condi-
tioning intensity, early withdrawal of immunosuppressive
agents, preemptive cellular therapy of donor lymphocyte
infusion (DLI) or natural killer cells, and post-HSCT mainte-
nance of hypomethylating agents (HMA) [8]. Therefore,
identiﬁcation of MDS patients with a high risk of relapse is
the ﬁrst and most important step for improving post-
transplantation survival outcomes.
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by novel DNA sequencing technologies, and up to 80% of
patients are known to have somatic genetic mutations [9-11].
Among the many genetic mutations, several genes such as
TP53, RUNX1, ETV6, EZH2, ASXL1, U2AF1, and SRSF2 have been
identiﬁed to have poor prognostic signiﬁcance in MDS [12-
15]. In addition to well-known clinical parameters, these
genetic and molecular markers could be used as prognostic
markers of transplantation outcomes in MDS. Unfortunately,
none of the markers are currently available for detection of
minimal residual disease (MRD) or prediction of relapse in a
HSCT setting. Several studies investigating post-
transplantation MRD in MDS have focused on Wilms tumor
gene 1 (WT1) expression [16,17].
From the early 1990s, WT1 expression has been specif-
ically studied in acute leukemia and the blast phase of
chronic myeloid leukemia. Such studies showed a high level
of WT1 expression in these diseases but not in indolent
disease or chronic leukemia [18,19]. Therefore, WT1 is likely
involved in the early stage of hematological cell differentia-
tion and its expression correlates with BM or peripheral
blood (PB) blast counts. Many studies have already investi-
gated the role of aberrant expression of WT1 as a marker for
residual disease in myeloid malignancy [20-22].
Several studies have reported that higherWT1 expression
at diagnosis or after induction chemotherapy is a signiﬁcant
predictor for relapse and worse survival outcomes in acute
myeloid leukemia (AML) [23-25], even after allo-HSCT
[26,27]. Also, in MDS patients, several studies reported the
utility ofWT1 expression. HigherWT1 expressionwas shown
to be associated with higher International Prognostic Scoring
System (IPSS) scores [28] and higher blast counts with poor
survival outcomes [29]. Recently, Lange et al. reported that
WT1 expression is also applicable after allo-HSCT, but further
studies are necessary because of the small number of
enrolled MDS patients [16].
In this study, we tried to identify the prognostic impact of
WT1 expression in 82 MDS patients receiving allo-HSCT by
analyzing the relationship betweenWT1 expression and pre-
and post-transplantation disease status. We also tried to
identify a clinically relevant cut-off level of WT1 expression
that could predict subsequent relapse independently of well-
known clinical predictors.
PATIENTS AND METHODS
Enrollment and Disease Risk Classiﬁcation
Adult MDS patients receiving HSCT from May 2009 to May 2013 at our
institution were screened. Subjects eligible for the study were those having
WT1 transcript results available at the time of HSCT and not receiving any
chemotherapeutic agents or cell therapy for the purpose of relapse pre-
vention. This retrospective study was approved by the institutional review
board of Seoul St. Mary’s Hospital, The Catholic University of Korea. MDS
patients diagnosed by French-American-British classiﬁcation [30] were
included and reclassiﬁed by World Health Organization (WHO) 2008 clas-
siﬁcation [31]. Risk stratiﬁcation was assessed by IPSS and risk groups that
were low and intermediate-1 were classiﬁed into lower risk MDS (LrMDS)
and those that were intermediate-2 and high into higher risk MDS (HrMDS)
[32]. In addition to IPSS at diagnosis, IPSS score was also assessed just before
the initial treatment, which consisted of HMA, intensive chemotherapy, or
HSCT. For analytical purposes, chronic myelomonocytic leukemia and MDS/
myeloproliferative neoplasms were also assessed by IPSS. BM blasts and
cytogenetic risk groups determined by IPSS, well-known predictors for
transplantation outcomes in patients with MDS, were also evaluated within
1 month before the conditioning regimen and used for disease character-
istics at the time of HSCT.
Pretransplantation Treatment Strategy
Pre-HSCT and HSCT treatment were performed according to the in-
stitution’s guidelines for MDS as described elsewhere [33]. Brieﬂy,immediate HSCT was planned for HrMDS, and bridging therapy with HMA
was planned for the preparation of HSCT when BM blast counts were 6% or
more. LrMDS patients with profound cytopenias with or without prior HMA
failure were considered candidates for HSCT. Standard protocols were used
for azacitidine (75mg/m2 for 7 days, every 28 days) or decitabine (20mg/m2
for 5 days, every 28 days). Intensive chemotherapy, consisting of an
anthracycline (idarubicin 12 mg/m2) for 3 days plus cytarabine (100 mg/m2
for 24 hours) for 7 days, was used to treat advanced diseases when patients
were evaluated to tolerate the treatment.
Transplantation Procedures
The intensity of the conditioning regimen for conventional donor HSCT
was selected according to the IPSS risk group at peak during the disease
course before HSCT. For HrMDS, a myeloablative conditioning (MAC)
regimen consisting of ﬂudarabine (150 mg/m2) plus 3.2 mg/kg/d i.v.
busulfan for 4 days (FB4) was used for 33 patients. For 28 patients with
LrMDS or some HrMDS patients who were older or had comorbidities, ﬂu-
darabine (150 mg/m2) plus 3.2 mg/kg/d i.v. busulfan for 2 days (FB2) was
used, according to our institution’s transplantation protocol [34]. For hap-
loidentical related donor transplantations (n ¼ 21), 400 or 800 cGy of total
body irradiation was added to FB2. For graft-versus-host disease (GVHD)
prophylaxis, patients undergoing HSCT from matched sibling donors
received cyclosporine and short-course methotrexate (10 mg/m2 i.v. on
daya þ1, þ3, þ6, and þ11), whereas patients with unrelated or hap-
loidentical related donors received tacrolimus and short-course metho-
trexate (5 mg/m2 i.v. on daya þ1, þ3, þ6, and þ11). GVHD prophylaxis with
rabbit antithymocyte globulin (Genzyme, Cambridge, MA) was added at a
median dose of 8 mg/kg (range, 2.5 to 10.0 mg/kg) for all recipients.
Assessment of WT1 Transcript Levels
WT1 transcript levels from BM samples were measured by real-time
quantitative PCR (WT1 ProﬁleQuant kit; Ipsogen, France). The assays were
performed in duplicate for greater accuracy. Real-time quantitative PCR
levels represented the ratio of WT1 expression to that of normal ABL1
expression (copies/104 ABL). In practice, serial monitoring ofWT1 expression
levels was planned before HSCT (within 1 month of conditioning), 1, 2 to 6,
and 7 to 12months after the day of stem cell infusion, and whenever relapse
was suspected. To determine the signiﬁcant cut-off level for relapse pre-
diction, we used receiver operating characteristic (ROC) curve analysis.
Statistical Analyses
The deﬁnition of transplantation-related events followed those
described in our previous report [34] and cause of death was deﬁned ac-
cording to the scheme by Copelan et al. [35]. GVHD was diagnosed and
graded according to consensus criteria [36-38]. All categorical variables
were compared by chi-square analysis and the Fisher’s exact test. Contin-
uous variables were assessed with the Student’s t-test or Mann-Whitney U
test for comparison between 2 groups, and Pearson analysis for calculating
correlation coefﬁcients. DFS rates were calculated using the Kaplan-Meier
survival method, and log-rank analysis was used to evaluate differences
between subgroups. Survival analyses were performed from the date of
stem cell infusion to the last date of analysis on March 31, 2014. Cumulative
incidence of relapse (CIR) and nonrelapse mortality were calculated by cu-
mulative incidence estimation, treating nonrelapse deaths and relapse as
competing risks, respectively. GVHD was also calculated by cumulative
incidence estimates, treating deaths and relapse as competing risks. All
results were compared using the Gray test [39]. Multivariate analyses by the
Cox’s proportional regression model were used to calculate the survival
hazard ratio. The signiﬁcance of factors affecting the CIR was determined
using a semi-parametric model known as the proportional hazardmodel for
subdistribution of competing risks. All statistical analyses were performed
using the Statistical Package for Social Sciences, version 14.0 (SPSS Inc.,
Chicago, IL). Cumulative incidence analyses were carried out with ‘R’ soft-
ware version 2.15.1 (R Foundation for Statistical Computing, 2012). Statis-
tical signiﬁcance was set at a P value <.05.
RESULTS
Patient Characteristics
Eighty-two patients with a median age of 49 (range, 20 to
66) years were enrolled in the study. Among the patients, 53
of 82 (64.6%) were male, and the median disease duration
before transplantation was 8.9 (range 3.0 to 173.8) months.
WHO-based diagnoses included 77 MDS, 3 chronic myelo-
monocytic leukemia, and 2 MDS/myeloproliferative
neoplasm. IPSS scores just before initial treatment showed
HrMDS in 41 (50.0%) patients and LrMDS in 41 (50.0%)
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received treatment before HSCT, 1 patient was treated with
intensive chemotherapy and 54 were treated with HMA,
which led to marrow complete remission in 24 (43.6%) pa-
tients, stable disease in 21 (38.2%) patients, and treatment
failure in 10 (18.2%) patients (6 [60.0%] HrMDS and 4 [40.0%]
LrMDS) at the time of HSCT. Changes in WHO-based di-
agnoses or IPSS risk during the clinical course until HSCT are
summarized in Table 1. All patients received PB stem cells of
which the graft source from donors was matched related
(n ¼ 32), suitably matched unrelated (n ¼ 29), or hap-
loidentical related (n ¼ 21).Table 1
Baseline Characteristics of Enrolled Patients
Characteristic Value
Total no. patients 82
Age, median (range), yr 49 (20-66)
Gender (male) 53 (64.6%)
WHO classiﬁcation at diagnosis
RCUD or RARS 6 (7.3%)
RCMD 30 (36.6%)
RAEB-1 18 (22.0%)
RAEB-2 21 (25.6%)
MDS-u 2 (2.4%)
MDS/MPN-u 2 (2.4%)
CMML 3 (3.7%)
WHO classiﬁcation at initial treatments
RCUD or RARS 3 (3.7%)
RCMD 30 (36.6%)
RAEB-1 11 (13.3%)
RAEB-2 30 (36.6%)
MDS-u 3 (3.7%)
MDS/MPN-u 2 (2.4%)
CMML 3 (3.7%)
Karyotype (IPSS risk) at diagnosis
Good 36 (43.9%)
Intermediate 27 (32.9%)
Poor 19 (23.2%)
IPSS score at diagnosis
Low 2 (2.4%)
Intermediate-1 44 (53.7%)
Intermediate-2 27 (32.9%)
High 9 (11.0%)
IPSS score at initial treatments
Low 1 (1.2%)
Intermediate-1 40 (48.8%)
Intermediate-2 33 (40.2%)
High 8 (9.8%)
Time from diagnosis to HSCT, median (range), mo 8.9 (3.0-173.8)
Treatment before HSCT
Best supportive care 27 (32.9%)
Azacitidine alone 28 (34.1%)
Decitabine alone 26 (31.7%)
Intensive chemotherapy alone 1 (1.2%)
Karyotype (IPSS risk) before HSCT
Good 40 (48.8%)
Intermediate 27 (32.9%)
Poor 15 (18.3%)
Marrow blast before HSCT, % (range) 3.0 (1-17)
HSCT donor
Matched sibling donor 32 (39.0%)
Unrelated donor 29 (35.4%)
Haploidentical related donor 21 (25.6%)
Conditioning intensity
MAC 33 (40.2%)
RIC 49 (59.8%)
CD34þcells, median (range), 106/kg 5.1 (.4-21.5)
CD3þ cells, median (range), 107/kg 41.9 (1.4-118.0)
RCUD indicates refractory cytopenia with unilineage dysplasia; RARS, re-
fractory anemia with ringed sideroblast; RCMD, refractory cytopenia with
multilineage dysplasia; MDS-u, myelodysplastic syndrome unclassiﬁable;
MPN, myeloproliferative neoplasm; CMML, chronic myelomonocytic leu-
kemia.
Data presented are n (%) unless otherwise indicated.Overall Transplantation Outcomes
A total of 28 patients developed acute GVHD  grade II
(grade II [n ¼ 17], grade III [n ¼ 5], and grade IV [n ¼ 6]). The
cumulative incidence of acute GVHD grade II at 3 years was
34.8%. Out of the 76 patients who survived at least 100 days
with sustained engraftment after HSCT, chronic GVHD
developed in 39 patients (mild [n ¼ 10], moderate [n ¼ 24],
and severe [n ¼ 5]), which resulted in an overall cumulative
incidence of 55.6%. After a median follow-up of 28.1 months
(range, 10.7 to 58.2 months) for surviving transplant re-
cipients, 55 patients (67.1%) remained alive. In all, 27 (32.9%)
of the 82 patients succumbed; 12 died of relapse and the
remaining 15 died of causes other than MDS. The primary
causes were acute GVHD (n ¼ 5), pneumonia (n ¼ 4), hem-
orrhagic cystitis (n¼ 1), cytomegalovirus colitis (n¼ 1), brain
abscess (n ¼ 1), viral meningitis (n ¼ 1), pulmonary hem-
orrhage (n¼ 1), and organ failure followed by veno-occlusive
disease (n ¼ 1). Persistent disease at 1 month after HSCT was
observed in 3 patients, and after which 12 patients relapsed
at a median of 4.3 (range, 2.1 to 24.1) months after HSCT.
Their WHO diagnoses at relapse were refractory cytopenia
with multilineage dysplasia in 10 patients, refractory anemia
with excess blasts (RAEB)-1 in 3 patients, and RAEB-2 in 2
patients; 3 of them remained alive after salvage treatment
including DLI, second allo-HSCT, or azacytidine therapy, all of
which induced additional GVHD. CIR and nonrelapse mor-
tality at 3 years were 21.5% and 16.0%, respectively, and 3-
year DFS and overall survival (OS) were 60.9%  2.8% and
65.0%  2.7%, respectively.
WT1 Transcript Levels According to Pre- and Post-HSCT
Disease Status
A total of 245 samples were assayed for WT1 transcripts;
82 samples before transplantation, 74 at 1 month, 49 at 2 to 6
months, and 40 at 7 to 12 months. First, we analyzed serial
changes of WT1 transcript levels. Median WT1 transcripts
were 996.5 copies/104 ABL (range, 10.3 to 15680.0) before
transplantation, 60.1 copies/104 ABL (range, 8.3 to 65,770.0)
at 1 month, 52.2 copies/104 ABL (range, 3.5 to 15,830.0) at 2
to 6 months, and 128.5 copies/104 ABL (range, 7.7 to 11,310.0)
at 7 to 12 months. When we calculated the log reduction of
WT1 expression at 1 month after HSCT compared with pre-
HSCT levels, the median log reduction was 1.0 log
(range, 2.4 log to 2.8 log). Comparison of WT1 transcripts
between MAC and RIC showed no signiﬁcant differences in
transcript levels at 1 month (median, 48.4 versus 87.7 copies/
104 ABL, P ¼ .077). However, the MAC regimen showed more
log reduction of WT1 expression (median, 1.3 log versus .8
log, P ¼ .026). Next, we determined whether WT1 transcript
levels differed according to disease status in pre- and post-
HSCT samples. We analyzed WT1 expression levels accord-
ing to pre-HSCT disease status from 82 samples, which
showed weak correlation with BM blast counts (r ¼ .157, P ¼
.025) and IPSS scores (r ¼ .189, P ¼ .013). We obtained 163
samples of post-transplantation WT1 transcripts and iden-
tiﬁed transcript levels according to the relapse status. WT1
transcript levels of 18 samples at various time points after
HSCT from 15 relapsed patients were signiﬁcantly higher in
comparison to those from 145 samples in remission (median,
13,420.0 [range, 53.7 to 65,770.0] versus 59.3 [range, 3.5 to
12,510.0] copies/104 ABL, P < .001). Further comparison of
WT1 transcript levels between relapsed and nonrelapsed
samples at given time points showed that median transcript
levels were signiﬁcantly different (Figure 1). The median
levels of relapsed versus nonrelapsed patients at 1 month, 2
Figure 1. Median WT1 transcript levels of relapsed and nonrelapsed samples
over the post-HSCT time period.
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3730.0 versus 46.1, and 2440.0 versus 109.0 copies/104 ABL,
respectively (P < .001). In patients with persistent disease
or relapse, the median WT1 transcript levels at the time of
relapse was 1640 copies/104 ABL (range, 210.0 to 9170.0)
in refractory cytopenia with multilineage dysplasia; 10,106
copies/104 ABL (range, 924.0 to 15,830.0) in RAEB-1; and
34,490 copies/104 ABL (range, 3210.0 to 65,770.0) in RAEB-2,
respectively. As a result, relapsed patients also showed
increased WT1 expression at the time of relapse compared
with the level at 1 month after HSCT (from 240.3 copies/104
ABL to 1760.0 copies/104 ABL, P ¼ .093).Figure 2. (A) ROC curve analysis revealed a signiﬁcant WT1 cut-off level at 1 month a
(>154 copies/104 ABL) WT1 expression at 1 month after HSCT showed signiﬁcantly hPrediction of Subsequent Relapse by WT1 Transcript
Levels
Next, we tried to identify the cut-off of WT1 expression
levels or its kinetics, which could predict subsequent relapse
by using ROC curve analysis on the results before HSCT and
those at 1 month. Pre- or post-HSCT WT1 expression results
from all 82 patients were analyzed for prediction of subse-
quent relapse afterWT1 assays. ForWT1 expression levels at
1 month after HSCT, results from 71 patients were used to
predict relapse after 1 month by usingWT1 expression levels
or WT1 log reduction, excluding cases with unavailable WT1
results (n¼ 8) or early relapse (n¼ 3). Neither pre-HSCTWT1
expression nor WT1 log reduction showed a signiﬁcant cut-
off for relapse prediction by ROC curve analysis. On the
contrary, 1-month post-HSCT WT1 expression revealed a
signiﬁcant cut-off for subsequent relapse prediction at 154
copies/104 ABL with 71.4% sensitivity and 83.3% speciﬁcity
(Figure 2A, area under curve¼ .840; P< .001). The 3-year CIR
rate was 47.2% (8 of 18 patients) in the higher WT1 group 1
month after HSCT and 6.9% (3 of 53 patients) in the lower
WT1 group 1 month after HSCT, which was signiﬁcantly
different (Figure 2B, P < .001). As a result, patients with
higher WT1 expression 1 month after HSCT also showed
poorer survival outcome. The 3-year DFS and OS rates were
41.7% and 54.3% in the higher WT1 group at 1 month after
HSCT, respectively, and 79.0% and 82.1% in the lower WT1
group at 1 month after HSCT, respectively (Figure 2C,D) (P ¼
.003 for DFS and P ¼ .033 for OS). Multivariate analyses
including clinical predictors showed that higher WT1
expression at 1 month (hazard ratio, 9.94; 95% conﬁdencefter HSCT that could predict subsequent relapse after allo-HSCT. (B-D), Higher
igher incidence of subsequent relapse and poorer DFS and OS.
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(hazard ratio, 3.52; 95% conﬁdence interval, 1.01 to 12.3, P ¼
.049) were signiﬁcantly predictive for subsequent relapse,
when adjusted with chronic GVHD as a time-dependent
covariate. Our data showed there was no deﬁnite associa-
tion between WT1 expression 1 month after HSCT and
development of chronic GVHD. Also, medianWT1 expression
level 1 month after HSCTof patients with chronic GVHD (71.9
copies/104 ABL) and without chronic GVHD (49.8 copies/104
ABL) was not statistically different (P ¼ .578). Higher WT1
expression 1 month also showed poorer DFS but OS was
not statistically signiﬁcant, whereas poor pre-HSCT karyo-
type and absence of chronic GVHD were signiﬁcantly pre-
dictive for poorer DFS and OS (Table 2). On the contrary, age,
disease duration, graft source, and conditioning intensity
were not signiﬁcantly associated with relapse, DFS, and OS.
Subgroup Analysis
As expected, MRD levels at 1 month induced by the
conditioning regimen could be further reduced by graft-
versus-leukemia (GVL) effects; therefore, we assessed the
association of GVHD and relapse among 18 patients with
higher WT1 expression 1 month after HSCT. Although the
statistical value was not signiﬁcant, chronic GVHD was
associated with a relatively lower incidence of relapse (25.0%
versus 60.0%, P ¼ .210) and superior DFS (75.0% versus 20.0%,
P ¼ .079) among patients with higher WT1 expression 1
month after HSCT, suggesting a preventive role of chronic
GVHD in patients with a higher risk of relapse. On the con-
trary, chronic GVHD was associated with superior OS (87.5%
versus 30.0%, P ¼ .019) in the group with higher WT1
expression 1 month after HSCT (Figure 3).
DISCUSSION
Our current study showed that higher WT1 expression at
any time point after HSCT was associated with hematologicalTable 2
One-Month Post-HSCT WT1 Additionally Adjusted with Other Parameters for Pred
Variables Relapse (CIR) DFS
Univariate Multivariate Univariate
3-Year CIR P HR (95% CI) P 3-Year DFS P
Age at diagnosis
>50 years 22.9% .574 59.8%
50 years 19.8% 62.2%
Karyotype at HSCT
Poor 41.7% .028* 3.52 (1.0-12.3) .049* 25.0% <
Not poor 16.6% 69.5%
BM blast at HSCT
>5% 29.7% .139 56.0%
5% 17.3% 63.2%
IPSS before treatments
Higher 26.9% .312 52.4%
Lower 14.6% 70.6%
Acute GVHD (Grade 2)
Present 23.1% .796 51.9%
Absent 20.7% 65.2%
Chronic GVHD
Present 13.5% .088 .43 (.1-1.7) .240 78.0% <
Absent 30.6% 43.6%
HSCT regimen
MAC (FB4) 15.2% .432 62.4%
RIC (FB2  TBI) 26.9% 58.7%
Post-HSCT 1 month WT1
>154 copies/104ABL 52.5% <.001* 9.94 (2.3-43.2) .002* 37.5%
154 copies/104ABL 8.7% 77.6%
HR indicates hazard ratio; CI, conﬁdential interval; TBI, total body irradiation.
* P < .05.relapse of MDS, suggesting that WT1 expression could be a
useful marker for disease status of MDS after transplantation.
Furthermore, we found that higherWT1 expression 1 month
after HSCT could predict subsequent relapse at a signiﬁcant
cut-off level of 154 copies/104 ABL in our cohort, thus indi-
cating a role ofWT1 expression as a relapse predictor. In this
study, we evaluatedWT1 expression as a marker of MRD and
predictor of relapse in a transplantation setting from a rela-
tively large cohort consisting of patients with MDSwhowere
treated with the same strategy at a single institution. As our
ﬁnal cut-off of 154 copies/104 ABL revealed 8 (44.4%) relapsed
patients out of 18 higher WT1 group with a relatively low
sensitivity (71%), we also regarded lower levels of the cut-off
associated with a higher sensitivity may be useful to identify
more patients at high risk of relapse earlier. However, when
we established the cut-off at the lower levels with higher
sensitivity (81.8% for 66 copies/104 ABL or 90.9% for 55
copies/104 ABL), 9 (28.1%) out of 32 patients and 9 (24.3%) out
of 37 patients showed subsequent relapse, respectively.
Lower cut-off showed only marginal gain of screening effect
of relapse prediction with lower speciﬁcity in our cohort.
Although many investigators have evaluated the utility of
WT1 expression in MDS, its role in an allo-HSCT setting has
not been fully elucidated. In our analyses, we ﬁrst evaluated
the role of pre-HSCT WT1 expression, which showed weak
correlations with BM blast counts and IPSS scores at the time
of HSCT. There was no signiﬁcant pre-HSCTWT1 cut-off level
for prediction of relapse. We reasoned that heterogeneity of
pretransplantation treatment modalities in the study cohort
might have affected the results. Therefore, the predictive role
of pre-HSCT WT1 expression and its kinetics in a trans-
plantation setting for MDS should be reassessed in cohorts
having homogeneous pre-HSCT treatment, as was previously
assessed in AML [26].
Our next analyses on post-HSCTWT1 expression revealed
that it could be used as a relapse predictor, similar toiction of Relapse, DFS, and OS
OS
Multivariate Univariate Multivariate
HR (95% CI) P 3-Year OS P HR (95% CI) P
.952 65.6% .790
67.8%
.001* 4.55 (1.6-12.4) <.001* 33.3% <.001* 6.58 (2.0-21.3) .001*
74.2%
.292 59.3% .239
70.9%
.212 58.8% .163
75.1%
.167 60.5% .256
69.4%
.001* .29 (.1-.8) .027* 85.8% <.001* .11 (.1-.4) .001*
47.9%
.877 68.9% .390
62.1%
.001* 3.19 (1.2-8.3) .010* 53.0% .028* 2.72 (.9-7.5) .053
80.6%
Figure 3. Clinical outcomes according to the development of chronic GVHD
among those patients with higher WT1 expression at 1 month after HSCT
(n ¼ 18).
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script levels from 20 MDS patients in addition to 68 de novo
AML patients receiving RIC HSCT for prediction of hemato-
logic relapse by 4 months. They showed that PB WT1
expression, BM CD34þ donor chimerism kinetics, and theircombination signiﬁcantly predict impending hematological
relapse within 28 days. Their assays, however, did not work
for later relapse, even within the following 84 days.
Comparedwith their study inwhichWT1 expression levels at
1 month were not shown to be signiﬁcantly different be-
tween the relapsed and nonrelapsed groups, our data
showed thatWT1 expression levels at 1 month could predict
subsequent relapse with 71.4% sensitivity and 83.3% speci-
ﬁcity. The discrepancy between the study by Lange et al. and
our study could be associated with differences in the number
of samples (12 versus 74) evaluated or the source of theWT1
assay (PB versus BM). The higher intensity of our condi-
tioning regimen could have also separated those cases with a
different risk of relapse at an early time point after HSCT.
Even though we observed a lower speciﬁcity of WT1
expression at 1 month compared with the prediction assays
proposed by Lange et al., our approach has practical impli-
cations for preventing overt hematological relapse in a clin-
ical setting. Early identiﬁcation 1 month after HSCT and
preemptive treatment to lessen tumor burden may result in
more effective treatment results and allow clinicians to do
more careful and step-by-step approaches to minimize
treatment toxicities, such as severe GVHD. Slow tapering of
immunosuppressive agents or preemptive DLI by escalating
doses rather than using bulk doses is an approach that has
been used [40]. Also, early identiﬁcation may optimize the
frequency of testing forWT1 expression according to the risk
of relapse. More frequent serial monitoring of WT1 expres-
sion after 1 month in patients with a high risk of relapse may
identify other cases at risk for later relapse. In addition to
immune modulation previously reported, another course
of immunotherapy or other novel therapies may be used in
patients still having higher WT1 expression. Induction of an
immune reaction against remnant MDS clones by WT1
cytotoxic T cell therapy, vaccines, or cytokine therapy can be
considered [41,42]. Novel agents including HMA, lenalido-
mide, or new targeted drugs can also be feasible treatment
options, which should be validated in the near future
[8,43,44]. For measurement of WT1 expression, using PB
samples might be more convenient for patients compared to
using BM samples, although the diagnosis of MDS mainly
depends on themorphological ﬁndings of BM. To identify the
possible utility of PB samples, several studies have already
showed that WT1 expression levels in PB and BM are well
correlated. Moreover, both of them tend to increase with
disease progression, including patients with a higher risk of
leukemic transformation in myeloid malignancy [22,25,29].
If a relevant cut-off level of PB WT1 expression for relapse
prediction and the range of PB WT1 expression in healthy
people are well validated, the results could be sufﬁcient
without performing repeated BM aspiration, especially for
serial monitoring after 1 month.
MRD at 1 month by quantiﬁcation ofWT1might not only
reﬂect the amount of MDS clones but could also be a
reﬂection of the sensitivity of MDS clones to chemothera-
peutic agents and, therefore, should be strongly associated
with the intensity of the conditioning regimen. Actually, our
MAC regimen showed a bigger WT1 log reduction and rela-
tively lower 1-month post-HSCT WT1 expression compared
with the RIC regimen. Of course, the intensity of conditioning
was primarily selected by disease risk and its inﬂuence on
relapse was, therefore, of no importance in our analysis.
However, the role of WT1 expression at 1 month remained
signiﬁcant when statistical analyses were performed sepa-
rately for MAC and RIC transplantations (data not shown).
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GVL effects accompanying acute and chronic GVHD [45,46].
Contrary to acute GVHD, chronic GVHD showed a lower CIR
rate and favorable DFS and OS, although its inﬂuence on
relapse did not reach statistical signiﬁcance in multivariate
analyses combined with WT1 expression at 1 month. How-
ever, especially in the 18 patients with higher post-HSCT
WT1 expression, 60.0% of patients without chronic GVHD
and 25.0% with chronic GVHD relapsed. Although this dif-
ference of relapse rate and DFS did not reach statistical po-
wer, OS was signiﬁcantly superior in the chronic GVHD
subgroup. We consider the lack of statistical power was
caused by a small patient number, and there might be a
possible GVL effect accompanied by chronic GVHD. There-
fore, induction of chronic GVHD should be considered with
caution to minimize its toxicity, especially in high-risk pa-
tients with elevated WT1 expression at 1 month after HSCT.
Although the results of this study are based on a retro-
spective analysis of a limited number of patients, our ob-
servations were from a cohort in which a consistent
treatment strategy, including immunosuppressive agents
and supportive management, were applied. We suggest that
WT1 expression 1 month after HSCT is useful for relapse
prediction in MDS patients receiving allo-HSCT. Further
analysis to identify a certain threshold level of WT1 expres-
sion in different conditioning regimens and its association
with other molecular markers or gene mutations should be
analyzed. Then, those results should be validated in large
prospective studies in the near future.
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